Erythropoietic Protoporphyria (EPP)
Metabolic·MeSH: Protoporphyria, Erythropoietic
Prevalence
0.1 / 100K
2 drugs in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| bitopertin | Disc Medicine, Inc. (IRON) |
Phase 2(1)
| Drug | Company |
|---|---|
| disc-1459 | Disc Medicine, Inc. (IRON) |
Compare drugs
Frequently asked questions
How many drugs are in development for Erythropoietic Protoporphyria (EPP)?
BioSniper tracks 2 drugs in development for Erythropoietic Protoporphyria (EPP) across 1 company.
How many clinical trials target Erythropoietic Protoporphyria (EPP)?
There are 2 clinical trials targeting Erythropoietic Protoporphyria (EPP) tracked by BioSniper.
What is the prevalence of Erythropoietic Protoporphyria (EPP)?
The estimated prevalence of Erythropoietic Protoporphyria (EPP) is approximately 0.1 per 100,000 population.
Deep-dive into Erythropoietic Protoporphyria (EPP)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis